273: Back to school for biotech, Biogen's potential pivot, & Illumina's next chapter

Josh Schimmer and Eric Schmidt, two longtime analysts teaming up at Cantor Fitzgerald, join us for a back-to-school conversation as biotech enters the busy back third of 2023. We also discuss the latest news in the life sciences, including some scientific evolution at Biogen, new leadership at Illumina, and the future of CRISPR medicine.

Episode metadata supplied by the publisher feed · Published Sep 7, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

273: Back to school for biotech, Biogen's potential pivot, & Illumina's next chapter

0:00 33:31

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Readout Loud?

This episode is 33 minutes long.

When was this The Readout Loud episode published?

This episode was published on September 7, 2023.

Can I download this The Readout Loud episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!